Genovefa Papanicolaou, MD
Infectious Disease · New York, NYNPI 1497726301
Payments from drug & device makers
Across 467 payments — averaging $5868.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2.2M
- Takeda Pharmaceuticals U.S.A., Inc.$253K
- Astellas Pharma Global Development$108K
- Shire North American Group Inc$101K
- Gilead$23K
- CSL Behring$15K
- plus $52K from 11 others
Across 18 payments — averaging $340.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Octapharma USA, Inc.$6K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 326 | $2,188,401 |
| Takeda Pharmaceuticals U.S.A., Inc. | 38 | $253,054 |
| Astellas Pharma Global Development | 13 | $108,419 |
| Shire North American Group Inc | 15 | $101,255 |
| Gilead | 3 | $22,861 |
| CSL Behring | 7 | $14,905 |
| Biotest AG | 2 | $9,211 |
| Partner Therapeutics, Inc. | 4 | $9,173 |
| Shionogi Inc | 14 | $7,983 |
| Octapharma USA, Inc. | 17 | $6,696 |
| ADMA Biomanufacturing LLC | 1 | $5,144 |
| Janssen Research & Development, LLC | 10 | $4,750 |
| Siemens Medical Solutions USA, Inc. | 2 | $3,735 |
| Astellas Pharma US Inc | 10 | $2,455 |
| Regeneron | 3 | $2,345 |
| Melinta Therapeutics, LLC | 1 | $73 |
| AstraZeneca | 1 | $18 |
How this compares
$2,740,477 in reported general payments places this provider in the 95th percentile of 799 infectious disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in New York
- Wafaa El SadrNew York$119.1M
- Judith AbergNew York$14.8M
- Magdalena SobieszczykNew York$2.9M
- Kristen MarksNew York$2.8M
- Thomas WalshNew York$1.4M
- Sean LiuNew York$1.4M
- Martin MarkowitzNew York$1.4M
- Angelica KottkampNew York$1.2M
- Michelle CespedesNew York$819K
- Vanessa RaabeNew York$728K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.